首页> 中文期刊> 《中国医院用药评价与分析》 >临床药师对小B细胞淋巴瘤行氟达拉滨和环磷酰胺方案化疗后伴发带状疱疹药物治疗的药学监护

临床药师对小B细胞淋巴瘤行氟达拉滨和环磷酰胺方案化疗后伴发带状疱疹药物治疗的药学监护

         

摘要

OBJECTIVE:To probe into the role of clinical pharmacists in drug therapy of herpes zoster induced by chemotherapy of fludalabine and cyclophosphamide regimen among patients with small B cell lymphoma .METHODS:Retrospective analysis was conducted on the participation of clinical pharmacists in the process of drug therapy of herpes zoster induced by chemotherapy of fludalabine and cyclophosphamide regimen in patients with small B cell lymphoma.RESULTS:The clinical pharmacists assisted the clinicians to formulate individualized treatment regimens ;and some suggestions for clinicians were adopted;the patient undergoing the 4 th period of chemotherapy regimens after improvement of herpes zoster , the patient had no special discomfort and was discharged from hospital . CONCLUSIONS:The participation of clinical pharmacists in formulation of individualized medication plan can reduce medication risk , guarantee the safety of drug use and promote the rational drug use .%目的:探讨临床药师在小B细胞淋巴瘤行氟达拉滨+环磷酰胺方案化疗后伴发带状疱疹药物治疗中的作用.方法:回顾性分析临床药师参与1例小B细胞淋巴瘤行氟达拉滨+环磷酰胺方案方案化疗后伴发带状疱疹患者的药物治疗过程.结果:临床药师协助临床医师制订了个体化治疗方案,临床医师采纳了临床药师的部分建议,患者带状疱疹好转后行第4周期化疗,过程顺利,患者无特殊不适并出院.结论:临床药师参与患者个体化用药方案的制订,可降低治疗风险,确保用药安全,促进合理用药.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号